Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,064,018 papers from all fields of science
Search
Sign In
Create Free Account
zanolimumab
Known as:
Anti-CD4 Monoclonal Antibody HuMax
, HuMax-CD4
A human IgG1k monoclonal antibody against the CD4 receptor on T-lymphocytes, with potential antineoplastic and immunosuppressing activities…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (1)
Monoclonal Antibodies
antigen binding
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2019
Highly Cited
2019
Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors
Marijo Bilusic
,
C. Heery
,
+9 authors
J. Gulley
Journal of Immunotherapy for Cancer
2019
Corpus ID: 201834430
BackgroundHuMax-IL8 (now known as BMS-986253) is a novel, fully human monoclonal antibody that inhibits interleukin-8 (IL-8), a…
Expand
Highly Cited
2017
Highly Cited
2017
Neutralization of IL-8 decreases tumor PMN-MDSCs and reduces mesenchymalization of claudin-low triple-negative breast cancer.
Charli L Dominguez
,
Kristen K. McCampbell
,
J. David
,
C. Palena
JCI Insight
2017
Corpus ID: 3283421
The complex signaling networks of the tumor microenvironment that facilitate tumor growth and progression toward metastatic…
Expand
Review
2011
Review
2011
Antibody-based therapeutics to watch in 2011
J. Reichert
mAbs
2011
Corpus ID: 12626878
This overview of 25 monoclonal antibody (mAb) and 5 Fc fusion protein therapeutics provides brief descriptions of the candidates…
Expand
Highly Cited
2010
Highly Cited
2010
Phase II trial of zanolimumab (HuMax‐CD4) in relapsed or refractory non‐cutaneous peripheral T cell lymphoma
F. d'Amore
,
J. Radford
,
+8 authors
H. Hagberg
British Journal of Haematology
2010
Corpus ID: 34687919
The efficacy and safety of zanolimumab (HuMax‐CD4) in patients with relapsed or refractory peripheral T Cell lymphoma (PTCL) was…
Expand
Review
2008
Review
2008
Newer monoclonal antibodies for hematological malignancies.
J. Castillo
,
E. Winer
,
P. Quesenberry
Experimental Hematology
2008
Corpus ID: 45228506
Highly Cited
2007
Highly Cited
2007
Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma.
Youn H. Kim
,
M. Duvic
,
+12 authors
S. Knox
Blood
2007
Corpus ID: 15375497
The efficacy and safety of zanolimumab in patients with refractory cutaneous T-cell lymphoma (CTCL) have been assessed in two…
Expand
2007
2007
Zanolimumab (HuMax-CD4™), a Fully Human Monoclonal Antibody: Efficacy and Safety in Patients with Relapsed or Treatment-Refractory Non-Cutaneous CD4+ T-Cell Lymphoma.
F. d'Amore
,
J. Radford
,
+9 authors
H. Hagberg
2007
Corpus ID: 78982459
Combination chemotherapy has been the basis of treatment for peripheral T-cell lymphoma (PTCL) for many years, but relapses are…
Expand
Highly Cited
2005
Highly Cited
2005
Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study.
B. Baslund
,
N. Tvede
,
+12 authors
I. McInnes
Arthritis & Rheumatism
2005
Corpus ID: 41227999
OBJECTIVE Interleukin-15 (IL-15) is a proinflammatory, innate response cytokine that mediates pleiotropic effector function in…
Expand
2005
2005
Treatment of a patient with a nodal peripheral T-cell lymphoma (Angioimmunoblastic T-cell lymphoma) with a human monoclonal antibody against the CD4 antigen (HuMax-CD4)
H. Hagberg
,
M. Pettersson
,
T. Bjerner
,
G. Enblad
Medical Oncology
2005
Corpus ID: 26404157
A patient with a CD4+ refractory peripheral T-cell lymphoma (PTL), subtype angioimmunoblastic T-cell lymphoma (AILD), was treated…
Expand
Highly Cited
2003
Highly Cited
2003
HuMax-CD4: a fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris.
L. Skov
,
K. Kragballe
,
+10 authors
O. Baadsgaard
Archives of Dermatology
2003
Corpus ID: 22731090
BACKGROUND Psoriasis is characterized by infiltration with mononuclear cells. Especially activated memory CD4+ T cells are…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE